Overview

The FUSIONPlex® Lung v2 panel is designed for RNA-based next-generation sequencing (NGS) using the patented Anchored Multiplex PCR (AMP™) technology.

AMP™ (Anchored Multiplex PCR) technology is a patented targeted enrichment platform for next-generation sequencing (NGS). It is based on the use of unidirectional gene-specific primers (GSPs) and molecular adapters with unique molecular barcodes (MBCs), which are ligated to the genetic material before amplification. This strategy enables the efficient capture and amplification of DNA, RNA or cfDNA fragments, even in the presence of unknown mutations or highly fragmented sequences.

Diagram of the Anchored Multiplex PCR technology used by the FUSIONPlex Lung v2 panel

The anchored primer architecture supports a flexible design and reduces information loss during library preparation. Combined with Archer™ Analysis software, AMP™ enables systematic error correction, read deduplication and accurate quantification of the original molecules, facilitating the detection of point variants, indels, gene fusions and copy number alterations with high sensitivity and specificity.

Non-small cell lung cancer

Protocol

Standard version

The panel is designed for use with Illumina® and Ion Torrent™ sequencers. The efficient workflow is structured around two rounds of multiplex PCR, with library preparation completed in approximately 1.5 days. It requires a minimum amount of RNA or total nucleic acid (TNA), typically between 10 and 250 ng, extracted from FFPE samples or other clinical sources.

HT version (high throughput)

The panel is optimised for high-throughput workflows and Illumina® sequencers. It enables the simultaneous preparation of multiple libraries in 96-well plates, using a scalable and automatable protocol that retains the sensitivity and accuracy of the standard design. An input amount of between 10 and 200 ng of RNA or TNA per sample is recommended, making it suitable for laboratories with high analytical workloads.

FUSIONPlex Lung v2 protocol workflow

Software

Archer™ Analysis is a comprehensive bioinformatics platform developed by IDT for the automated analysis of NGS data generated with panels from the Archer® family, including FUSIONPlex™, VARIANTPlex™ and LIQUIDPlex™. It enables comprehensive molecular analyses from DNA or RNA, adapted to each sample type and clinical or research application. It is compatible with sequencing data from Illumina® platforms —FUSIONPlex™, VARIANTPlex™ and LIQUIDPlex™— and Ion Torrent™ —FUSIONPlex™ only—. The platform runs pipelines optimised for each technology. For FUSIONPlex™, it supports the detection of known and de novo gene fusions, splicing variants, exon-skipping events and gene expression levels from RNA. Archer™ Analysis provides an intuitive and secure web interface that enables users to view detected variants, apply custom filters, generate automated reports and perform clinical annotation using tools such as ClinVar, COSMIC and Ensembl, among other reference databases. Designed for regulated environments, it provides complete traceability, reproducible analyses and scalability for laboratories working with advanced genomic profiling in cancer, from research through to clinical applications under RUO or CE-IVD marking, depending on the panel configuration.

Specifications

Broad detection capabilities: known and de novo fusions, splicing variants, SNVs, insertions, deletions and RNA expression.

Detection capabilities of the FUSIONPlex Lung v2 panel
AMP™ technology Improves sensitivity and accuracy in the detection of genetic alterations.
Optimised for FFPE Suitable for low-quality samples.
Starting amount of genetic material Requires only 10 ng of RNA.
Universal compatibility Compatible with Illumina® and Ion Torrent™ sequencers.
Bioinformatics support Includes the Archer™ Analysis platform for data analysis and visualisation.

Complete gene list

Complete gene list for the FUSIONPlex Lung v2 panel Click the image to enlarge the gene list.

Area:

Fusions, Respiratory System, Solid tumor, Tumor Types

Brand:

Documents:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

SureSelect Cancer CGP Assay

Targeted-enrichment NGS pan-cancer panel for comprehensive genomic profiling (CGP) of solid tumours. Designed to detect somatic variants at DNA level (SNVs, indels, CNVs, translocations) and RNA level (gene fusions), as well as to assess complex immuno-oncology biomarkers such as tumour mutational burden (TMB), microsatellite instability (MSI) and homologous recombination deficiency (HRD). Detailed Description Operating principle…
Agilent
Next Generation Sequencing (NGS)

SeqOne HRD Solution con Agilent SureSelect CD HRR17 Panel

HRD analysis solution combining low-coverage whole-genome sequencing (shallow/low-pass WGS) and a targeted gene panel to detect genomic instability, BRCA1/2 alterations and other genes related to homologous recombination. It is designed for laboratories wishing to implement HRD testing in-house with an automated, efficient and clinically validated workflow. Detailed Description SeqOne’s HRD solution combines shallow WGS and…
Agilent
Next Generation Sequencing (NGS)

OncoSELECT®

Comprehensive targeted liquid biopsy assay designed to support decision-making in oncology through the analysis of 74 clinically relevant genes. The solution encompasses everything from library preparation reagents to bioinformatics analysis, clinical interpretation and the generation of detailed reports. 3.- Detailed Description Operating principle OncoSELECT® is an advanced liquid biopsy panel based on circulating cell-free DNA…
OncoDNA
Next Generation Sequencing (NGS)

MSK-ACCESS® powered with SOPHiA DDM™

In-house liquid biopsy solution based on hybrid-capture next-generation sequencing (NGS) technology for the ultrasensitive detection of somatic alterations in circulating cell-free DNA from plasma. Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it implements a robust matched tumor-normal sequencing approach (plasma cfDNA + white blood cell DNA) to filter germline variants and mutations…
SOPHIA Genetics
Next Generation Sequencing (NGS)